Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018 / 임상당뇨병
Journal of Korean Diabetes
;
: 6-9, 2019.
Artigo
em Coreano
| WPRIM
| ID: wpr-761472
ABSTRACT
In 2018, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a consensus recommendation on management of hyperglycemia. This consensus report emphasized the need for patient-centered management considering multimorbidity and individual patient preferences and barriers. Patients with type 2 diabetes with established atherosclerotic cardiovascular disease who fail to control blood glucose with the initial glucose-lowering medication are recommended a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist. For patients with chronic kidney disease and heart failure, SGLT2 inhibitors are recommended. In patients who need an injectable medication, GLP-1 receptor agonists are the preferred choice over insulin. In this section, we summarize “Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).”
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Glicemia
/
Doenças Cardiovasculares
/
Comorbidade
/
Assistência Centrada no Paciente
/
Consenso
/
Diabetes Mellitus
/
Insuficiência Renal Crônica
/
Aterosclerose
/
Peptídeo 1 Semelhante ao Glucagon
/
Preferência do Paciente
Tipo de estudo:
Guia de Prática Clínica
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of Korean Diabetes
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS